<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" article-type="brief-report" dtd-version="1.3" xml:lang="EN">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">Front. Pharmacol.</journal-id>
<journal-title-group>
<journal-title>Frontiers in Pharmacology</journal-title>
<abbrev-journal-title abbrev-type="pubmed">Front. Pharmacol.</abbrev-journal-title>
</journal-title-group>
<issn pub-type="epub">1663-9812</issn>
<publisher>
<publisher-name>Frontiers Media S.A.</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="publisher-id">1769137</article-id>
<article-id pub-id-type="doi">10.3389/fphar.2026.1769137</article-id>
<article-version article-version-type="Version of Record" vocab="NISO-RP-8-2008"/>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Brief Research Report</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Sphingosine-1-phosphate receptor signaling regulates an ERK1/2&#x2013;p65 molecular switch in macrophages during <italic>Leishmania donovani</italic> infection</article-title>
<alt-title alt-title-type="left-running-head">Arish and Naz</alt-title>
<alt-title alt-title-type="right-running-head">
<ext-link ext-link-type="uri" xlink:href="https://doi.org/10.3389/fphar.2026.1769137">10.3389/fphar.2026.1769137</ext-link>
</alt-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" corresp="yes">
<name>
<surname>Arish</surname>
<given-names>Mohd</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref>
<xref ref-type="corresp" rid="c001">&#x2a;</xref>
<uri xlink:href="https://loop.frontiersin.org/people/716650"/>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; original draft" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-original-draft/">Writing - original draft</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; review &#x26; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/Writing - review &#x26; editing/">Writing - review and editing</role>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name>
<surname>Naz</surname>
<given-names>Farha</given-names>
</name>
<xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref>
<xref ref-type="corresp" rid="c001">&#x2a;</xref>
<uri xlink:href="https://loop.frontiersin.org/people/973962"/>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; review &#x26; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/Writing - review &#x26; editing/">Writing - review and editing</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; original draft" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-original-draft/">Writing - original draft</role>
</contrib>
</contrib-group>
<aff id="aff1">
<label>1</label>
<institution>JH-Institute of Molecular Medicine, Jamia Hamdard</institution>, <city>New Delhi</city>, <country country="IN">India</country>
</aff>
<aff id="aff2">
<label>2</label>
<institution>Division of Infectious Disease and International Health, Department of Medicine, University of Virginia</institution>, <city>Charlottesville</city>, <state>VA</state>, <country country="US">United States</country>
</aff>
<author-notes>
<corresp id="c001">
<label>&#x2a;</label>Correspondence: Mohd Arish, <email xlink:href="mailto:dr.mohdarish@gmail.com">dr.mohdarish@gmail.com</email>; Farha Naz, <email xlink:href="mailto:Farha64@gmail.com">Farha64@gmail.com</email>
</corresp>
</author-notes>
<pub-date publication-format="electronic" date-type="pub" iso-8601-date="2026-02-10">
<day>10</day>
<month>02</month>
<year>2026</year>
</pub-date>
<pub-date publication-format="electronic" date-type="collection">
<year>2026</year>
</pub-date>
<volume>17</volume>
<elocation-id>1769137</elocation-id>
<history>
<date date-type="received">
<day>16</day>
<month>12</month>
<year>2025</year>
</date>
<date date-type="rev-recd">
<day>13</day>
<month>01</month>
<year>2026</year>
</date>
<date date-type="accepted">
<day>20</day>
<month>01</month>
<year>2026</year>
</date>
</history>
<permissions>
<copyright-statement>Copyright &#xa9; 2026 Arish and Naz.</copyright-statement>
<copyright-year>2026</copyright-year>
<copyright-holder>Arish and Naz</copyright-holder>
<license>
<ali:license_ref start_date="2026-02-10">https://creativecommons.org/licenses/by/4.0/</ali:license_ref>
<license-p>This is an open-access article distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License (CC BY)</ext-link>. The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</license-p>
</license>
</permissions>
<abstract>
<p>
<italic>Leishmania donovani</italic> establishes intracellular infection by suppressing macrophage inflammatory responses. Although sphingosine-1-phosphate (S1P) signaling is known to regulate macrophage function, the receptor isotype&#x2013;specific mechanisms involved during <italic>Leishmania donovani</italic> infection remain unclear. In this study, we examined the role of individual S1P receptors (S1PR1&#x2013;3) in modulating macrophage responses to <italic>L. donovani.</italic> Using <italic>L. donovani&#x2013;</italic>infected THP-1&#x2013;derived human macrophages, selective pharmacological agonists of S1PR1, S1PR2, and S1PR3 were employed to assess intracellular signaling, inflammatory mediator production, and parasite burden. Activation of S1PR signaling differentially regulated an ERK1/2&#x2013;NF-&#x3ba;B p65 molecular switch, marked by reduced ERK1/2 phosphorylation and enhanced p65 phosphorylation. These changes were associated with decreased IL-10 levels, increased TNF-&#x3b1; and nitric oxide production, and reduced intracellular parasite load. While activation of all three receptor isotypes limited parasite survival, S1PR2 produced the most pronounced inflammatory and anti-leishmanial effects, indicating functional divergence among S1PRs. These findings highlight receptor-specific roles of S1PR signaling in macrophage responses during <italic>L. donovani</italic> infection.</p>
</abstract>
<kwd-group>
<kwd>ERK (extracellular signal-regulated kinase)</kwd>
<kwd>
<italic>L. donovani</italic>
</kwd>
<kwd>macrophages</kwd>
<kwd>Nf-&#x3ba;b (nuclear factor-kappa b)</kwd>
<kwd>sphingosine-1-phosphate signaling</kwd>
</kwd-group>
<funding-group>
<award-group id="gs1">
<funding-source id="sp1">
<institution-wrap>
<institution>Department of Health Research, India</institution>
<institution-id institution-id-type="doi" vocab="open-funder-registry" vocab-identifier="10.13039/open_funder_registry">10.13039/501100009104</institution-id>
</institution-wrap>
</funding-source>
<award-id rid="sp1">R.12014/15/2018-HR</award-id>
</award-group>
<funding-statement>The author(s) declared that financial support was not received for this work and/or its publication.</funding-statement>
</funding-group>
<counts>
<fig-count count="2"/>
<table-count count="0"/>
<equation-count count="0"/>
<ref-count count="33"/>
<page-count count="7"/>
</counts>
<custom-meta-group>
<custom-meta>
<meta-name>section-at-acceptance</meta-name>
<meta-value>Pharmacology of Infectious Diseases</meta-value>
</custom-meta>
</custom-meta-group>
</article-meta>
</front>
<body>
<sec sec-type="intro" id="s1">
<title>Introduction</title>
<p>Macrophages are highly plastic cells of the immune system that offer protection against various intracellular pathogens. However, intracellular pathogens exploit macrophages by taking advantage of macrophage plasticity, resulting in disease progression (<xref ref-type="bibr" rid="B1">Arish and Naz, 2022a</xref>). <italic>Leishmania donovani</italic> (AG83) strain, causative agent for Visceral Leishmaniasis, is a protozoan parasite that can infect macrophages (<xref ref-type="bibr" rid="B16">Lang et al., 1994</xref>). BALB/c mice are highly susceptible to <italic>Leishmania</italic> infection, as they fail to polarize macrophages toward a protective M1 phenotype, instead favoring a Th2-driven environment that allows the parasite to persist (<xref ref-type="bibr" rid="B6">Bodhale et al., 2018</xref>). Diseased susceptible macrophages are often characterized by anti-inflammatory phenotypes, while host-protective phenotypes are associated with inflammatory responses such as increased inducible nitric oxide (iNOS), Interleukin (IL)-12, and Tumor necrosis factor (TNF)-&#x3b1; production (<xref ref-type="bibr" rid="B7">Carneiro et al., 2021</xref>). Hence, macrophage reprograming from anti-inflammatory to pro-inflammatory can be used as an adjunctive therapy for the management of Leishmaniasis (<xref ref-type="bibr" rid="B23">Palomino-Cano et al., 2024</xref>).</p>
<p>Sphingosine-1-phosphate (S1P) signaling has been reviewed as an important drug target against several infectious diseases (<xref ref-type="bibr" rid="B3">Arish et al., 2016</xref>; <xref ref-type="bibr" rid="B22">Naz et al., 2024</xref>). Previously, we studied the role of S1P signaling in clearing intracellular <italic>L. donovani</italic> and <italic>Mycobacteria tuberculosis</italic> infection through activation of S1P signaling. This leads to macrophages activation to secret pro-inflammatory mediators such as IL-12 or IL-6 that further leads to infection clearance (<xref ref-type="bibr" rid="B5">Arish et al., 2018</xref>; <xref ref-type="bibr" rid="B2">Arish and Naz, 2022b</xref>). As S1P signaling could be mediated through its five isotypes, named as S1P receptor (S1PR) 1&#x2013;5 (<xref ref-type="bibr" rid="B4">Arish et al., 2017</xref>; <xref ref-type="bibr" rid="B21">McGinley and Cohen, 2021</xref>). Monocytes and macrophages express multiple S1PRs primarily S1PR1, S1PR2, and S1PR3 and is crucial for their migration, recruitment to inflammation sites, phagocytosis, and inflammatory responses, where S1PR1 often promotes anti-inflammatory effects and S1PR2/3 drive pro-inflammatory actions like pro-IL1&#x3b2;, IL-18, and TNF-&#x3b1;,release (<xref ref-type="bibr" rid="B20">Lin et al., 2024</xref>; <xref ref-type="bibr" rid="B28">Wang et al., 2023</xref>; <xref ref-type="bibr" rid="B29">Weigert et al., 2019</xref>). Although S1PR4/5 expression is found in low levels in macrophages, its role in regulation of macrophage function is largely unknow (<xref ref-type="bibr" rid="B29">Weigert et al., 2019</xref>). THP-1 derived macrophages only express S1PR1-3 and play important role in macrophage polarization following Mtb infection (<xref ref-type="bibr" rid="B2">Arish and Naz, 2022b</xref>). Nevertheless, the role of S1P signaling was studied previously (<xref ref-type="bibr" rid="B5">Arish, et al., 2018</xref>), receptor specific anti-leishmanial responses and underlying molecular mechanisms in context of <italic>L. donovani</italic> infection was not well understood.</p>
<p>In the present study, we further elucidate the role of S1P signaling in regulating the extracellular signal-regulated kinase (ERK) and nuclear factor kappa B (NF-&#x3ba;B) pathways during <italic>L. donovani</italic> infection. As S1P is a natural ligand of S1PRs, we used specific S1PR1-3 agonists, named as CYM5442, CYM5520, and CYM5541, respectively, to further examine the exact receptor-mediated anti-leishmanial response. CYM5442 is a potent and selective agonist of S1PR1 (<xref ref-type="bibr" rid="B11">Gonzalez-Cabrera et al., 2008</xref>), CYM5520 selectively activates S1PR2 without cross-reactivity to other (<xref ref-type="bibr" rid="B25">Satsu et al., 2013</xref>), and CYM5541 exhibits preferential activation of S1PR3 (<xref ref-type="bibr" rid="B13">Jo et al., 2012</xref>). In this study we looked for ERK1/2 and p65 activation status in S1PR1-3-agonist treated <italic>L. donovani</italic>-infected THP-1 derived macrophages. As S1P signaling have previously shown induction of pro-inflammatory functions of the macrophages (<xref ref-type="bibr" rid="B27">Tian et al., 2023</xref>; <xref ref-type="bibr" rid="B32">Yang et al., 2018</xref>), we next assessed the capacity of S1PR1-3 in eliminating intracellular <italic>L. donovani</italic> infection.</p>
</sec>
<sec sec-type="methods" id="s2">
<title>Methods</title>
<sec id="s2-1">
<title>Human macrophage cell line</title>
<p>The THP-1 cell line was maintained in RPMI 1640 medium (Life Technologies) supplemented with 10% heat-inactivated FBS (Life Technologies) and 100&#xa0;U/mL penicillin and 100&#xa0;&#x3bc;g/mL streptomycin formulation (Life Technologies) at 37&#xa0;&#xb0;C in 5% CO<sub>2</sub>. PMA (phorbol 12-myristate 13-acetate; Sigma) was used for differentiation of THP-1 monocytes into macrophages by incubating THP-1 monocytes for 24&#xa0;h with 5&#xa0;ng/mL PMA, followed by 24&#xa0;h resting at 37&#xa0;&#xb0;C in 5% CO<sub>2</sub> in flat-bottom 12-well tissue culture plates (BD Biosciences). To preserve the optimal phenotype of THP-1 monocytes, the cell line was not passaged more than 20 times.</p>
</sec>
<sec id="s2-2">
<title>Parasite</title>
<p>The standard strain of <italic>L. donovani</italic>: (MHOM/IN/83/AG83) was maintained in M199 media (Life Technologies) with 25&#xa0;mM HEPES (Sigma) and supplemented with 10% heat-inactivated Fetal bovine serum (Life Technologies) with 100&#xa0;U/mL penicillin and 100&#xa0;&#x3bc;g/mL streptomycin formulation (Life Technologies) at 22&#xa0;&#xb0;C. Mid-log phase culture was used to infect differentiated THP-1 cells. <italic>Leishmania donovani</italic> strain used in this study was routinely passaged through mouse infection and periodically revived from low-passage frozen stocks.</p>
</sec>
<sec id="s2-3">
<title>Infection of macrophages</title>
<p>THP-1 derived macrophages were harvested and distributed into 12-well plates at 1 &#xd7; 10<sup>6</sup>/mL. Promastigotes were added to differentiated macrophages at an infection ratio of 1:10 for 6&#xa0;h to initiate infection. Infected macrophages were further replenished with supplemented RPMI 1640 containing 10% FBS for an additional 24&#xa0;h for different studies.</p>
</sec>
<sec id="s2-4">
<title>Parasite load</title>
<p>Macrophages were seeded on poly-L-lysine&#x2013;coated sterile coverslips placed in 12-well culture plates at a density of 1 &#xd7; 10<sup>6</sup> cells/mL. Cells were infected with <italic>L. donovani</italic> at a 1:10 ratio for 6&#xa0;h, after which extracellular parasites were gently removed by washing. Infected cells were treated with 10&#xa0;&#x3bc;M S1PR1-3 agonist and cultured for an additional 24&#xa0;h.</p>
<p>Following incubation, cells were washed with PBS, fixed with ice-cold methanol for 5&#xa0;min, and air-dried. Coverslips were then immersed in Giemsa stain for 30&#xa0;min and washed 2&#x2013;3 times with PBS. For each condition, at least 15 randomly selected fields were examined microscopically to determine the average number of parasites per macrophage. Parasite load for each treatment was expressed as a percentage relative to the control group, which was set at 100%.</p>
</sec>
<sec id="s2-5">
<title>Protein extraction and western blotting</title>
<p>Following experimental treatments, infected and uninfected THP-1&#x2013;derived macrophages were washed twice with ice-cold phosphate-buffered saline (PBS) and lysed using ice-cold lysis buffer (Cell Signaling Technology) supplemented with 1&#xd7; protease inhibitor cocktail and 1&#xd7; phosphatase inhibitor cocktail (Sigma). Cell lysates were clarified by centrifugation at 14,000 &#xd7; g for 15&#xa0;min at 4&#xa0;&#xb0;C, and the supernatants were collected.</p>
<p>Protein concentrations were determined using a commercial protein quantification assay according to the manufacturer&#x2019;s instructions (Bradford assay, Bio-Rad). Equal amounts of protein (approximately 80&#xa0;&#xb5;g per lane) were mixed with SDS sample buffer (ThermoScientific), denatured by heating, and resolved by SDS&#x2013;PAGE on 12% polyacrylamide gels using commercially available running buffer. Proteins were subsequently transferred onto polyvinylidene difluoride (PVDF) membranes using a commercially available transfer buffer supplemented with 20% methanol.</p>
<p>Following transfer, membranes were blocked in blocking buffer and incubated with primary antibodies against phospho-ERK1/2, total ERK1/2, phospho-NF-&#x3ba;B p65, total p65, and &#x3b2;-actin (Cell Signaling Technology). After washing with wash buffer, membranes were incubated with appropriate horseradish peroxidase&#x2013;conjugated secondary antibodies. Immunoreactive bands were detected using a chemiluminescence-based detection system according to the manufacturer&#x2019;s instructions. Band intensities were quantified by densitometric analysis using ImageJ software and normalized to &#x3b2;-actin or the corresponding total protein levels, as indicated.</p>
</sec>
<sec id="s2-6">
<title>Enzyme-linked immunosorbent assay</title>
<p>Cytokine levels in culture supernatants from <italic>L. donovani-</italic>infected and uninfected THP-1-derived macrophages with or without S1PR1-3 agonist were quantified using BD Biosciences ELISA kits, following the manufacturer&#x2019;s protocol with minor optimizations. Briefly, supernatants were collected at indicated time points, centrifuged at 300 &#x00d7;&#xa0;<italic>g</italic> for 5&#xa0;min to remove cellular debris, and stored at &#x2212;80&#xa0;&#xb0;C until analysis. Ninety-six-well plates were coated with capture antibody (100 &#xb5;L/well) and incubated overnight at 4&#xa0;&#xb0;C. After washing with PBS containing 0.05% Tween-20, wells were blocked with assay diluent for 1&#xa0;h at room temperature. Samples and serially diluted standards were added in duplicate (100 &#xb5;L/well) and incubated for 2&#xa0;h at room temperature. Plates were washed three times and incubated with biotin-conjugated detection antibody (100 &#xb5;L/well) for 1&#xa0;h, followed by streptavidin-HRP (100 &#xb5;L/well) for 30&#xa0;min in the dark. TMB substrate (100 &#xb5;L/well) was added, and the reaction was stopped with 50&#xa0;&#xb5;L stop solution. Absorbance was measured at 450&#xa0;nm with a 570&#xa0;nm reference using a microplate reader. Cytokine concentrations were determined from standard curves using four-parameter logistic regression.</p>
</sec>
<sec id="s2-7">
<title>Nitric oxide assay</title>
<p>Nitric oxide (NO) production was measured using the Nitric Oxide Assay Kit (Thermo Scientific), which quantifies total nitrite as an indicator of NO. Cell-free supernatants were mixed with equal volumes of Griess reagent (50&#xa0;&#xb5;L &#x2b; 50&#xa0;&#xb5;L) in 96-well plates and incubated at room temperature for 10&#xa0;min in the dark. Nitrite standards (0&#x2013;100&#xa0;&#xb5;M) were prepared in culture medium to account for background. Absorbance was recorded at 540&#xa0;nm, and nitrite concentrations were interpolated from the standard curve. All measurements were performed in triplicate and expressed as &#xb5;M nitrite per mL of culture supernatant.</p>
</sec>
<sec id="s2-8">
<title>Statistical analysis</title>
<p>The statistical analysis was performed using GraphPad Prism, version 7.0 (GraphPad, San Diego, CA, USA). To ascertain the significance of the difference between the means of two samples Student&#x2019;s t-test was used. One-way ANOVA with Tukey test was performed for multiple comparisons. The error bars of the values represent &#xb1; SD from the replicates. The results shown are a representation from a minimum of three similar experiments that generated reproducible data.</p>
</sec>
</sec>
<sec sec-type="results" id="s3">
<title>Results</title>
<sec id="s3-1">
<title>Reciprocal regulation of pro and anti-inflammatory profiles in macrophages by S1PR1-3 agonists</title>
<p>
<italic>Leishmania donovani</italic> infection has been previously shown to suppress macrophage-mediated inflammatory responses to facilitate its intracellular persistence (<xref ref-type="bibr" rid="B12">Gupta et al., 2016</xref>). It is previously known that <italic>L. donovani</italic> modulates ERK and NF-&#x3ba;B pathways (<xref ref-type="bibr" rid="B24">Reinhard et al., 2012</xref>; <xref ref-type="bibr" rid="B31">Yang et al., 2007</xref>). To determine whether S1PR modulators can modulate ERK signaling and NF-&#x3ba;B pathway, we treated <italic>L. donovani</italic>&#x2013;infected THP-1&#x2013;derived macrophages with selective agonists of S1PR1&#x2013;3 (10&#xa0;&#x3bc;M). As THP-1&#x2013;derived macrophages express S1PR1&#x2013;3 (<xref ref-type="bibr" rid="B5">Arish et al., 2018</xref>) only these receptor agonists were used in this study. We observed that activation of S1PR2 and S1PR3 significantly reduced ERK phosphorylation in infected macrophages (<xref ref-type="fig" rid="F1">Figures 1A,B</xref>).</p>
<fig id="F1" position="float">
<label>FIGURE 1</label>
<caption>
<p>Reciprocal regulation of pro and anti-inflammatory profiles in macrophages by S1PR1-3 agonists THP-1 derived macrophages were cultured in six-well plates in the presence of <italic>L. donovani</italic> infection (MOI &#x3d; 1:10) for 6&#xa0;h, infected macrophages (IM) were washed to remove non-internalized parasites and incubated for next 24&#xa0;h in presence or absence of 10&#x3bc;M S1PR1, S1PR2, and S1PR3 agonist, respectively <bold>(A)</bold> Western Blot analysis showing p65 and ERK1/2 phosphorylation. <bold>(B)</bold> Densitometry analysis of pERK western blot <bold>(C)</bold> Densitometry analysis of p65 western blot <bold>(D)</bold> IL-10 production in <italic>L. donovani</italic> infected and uninfected THP-1 derived macrophages (UIM) supplemented with S1PR1-3 agonists for additional 24&#xa0;h <bold>(E)</bold> TNF&#x3b1; production in <italic>L. donovani</italic> infected and uninfected THP-1 derived macrophages supplemented with S1PR1-3 agonists for additional 24&#xa0;h <bold>(F)</bold> NO production in <italic>L. donovani</italic> infected and uninfected THP-1 derived macrophages supplemented with S1PR1-3 agonists for additional 24&#xa0;h. The data is a representation of mean &#xb1; SD from three independent experiments &#x2a;, p&#x3c; 0.05; &#x2a;&#x2a;, p&#x3c; 0.01; &#x2a;&#x2a;&#x2a;, p &#x3c; 0.001;ns non-significant.</p>
</caption>
<graphic xlink:href="fphar-17-1769137-g001.tif">
<alt-text content-type="machine-generated">Panel A shows Western blot analysis for pp65, p65, pERK1/2, ERK1/2, and &#x3B2;-Actin with different treatments. Panels B and C display bar graphs of pERK/&#x3B2;-Actin and pp65/&#x3B2;-Actin ratios across conditions, with significance indicated. Panels D, E, and F show bar graphs of IL-10, TNF&#x3B1;, and NO levels, respectively, with annotations for statistical significance.</alt-text>
</graphic>
</fig>
<p>NF-&#x3ba;B activation is required for protection against <italic>L. donovani</italic> infection (<xref ref-type="bibr" rid="B24">Reinhard et al., 2012</xref>). To assess NF-&#x3ba;B activation, we next analyzed phospho-p65 (Rel/A) levels following S1PR1&#x2013;3 agonist treatment. Notably, S1PR1&#x2013;2 agonists induced non-significant increase in NF-&#x3ba;B activation in infected THP-1 macrophages. However, S1PR3 agonist showed significant increase expression of pp65 (<xref ref-type="fig" rid="F1">Figures 1A,C</xref>). As ERK phosphorylation leads to IL-10 production (<xref ref-type="bibr" rid="B31">Yang et al., 2007</xref>), we checked if this decrease in phospho-ERK level leads to low IL-10 production in infected macrophages after activation of S1P signaling. We observed that after S1PR1-3 agonist supplementation, there was low level of IL-10 detected in the supernatant in the infected macrophages (<xref ref-type="fig" rid="F1">Figure 1D</xref>). Given our previous observation that S1P signaling enhances TNF&#x3b1; production in <italic>M. tuberculosis</italic>&#x2013;infected macrophages (<xref ref-type="bibr" rid="B2">Arish and Naz, 2022b</xref>), we investigated whether a similar effect occurs in <italic>L. donovani</italic> infection. Consistent with this, TNF&#x3b1; production was significantly elevated in infected macrophages following S1P pathway activation (<xref ref-type="fig" rid="F1">Figure 1E</xref>).</p>
<p>Finally, we assessed NO production, as NF-&#x3ba;B activity has been reported to regulate NO synthesis (<xref ref-type="bibr" rid="B14">Jones et al., 2007</xref>; <xref ref-type="bibr" rid="B19">Li et al., 2002</xref>). In agreement with our previous findings that S1PR1&#x2013;3 modulators promote NO generation in THP-1 macrophages during <italic>M. tuberculosis</italic> infection (<xref ref-type="bibr" rid="B2">Arish and Naz, 2022b</xref>), we observed a significant increase in NO levels specifically in the S1PR2 agonist&#x2013;treated group, with non-significant increase following S1PR3 agonist treatment as compared to infected macrophages (<xref ref-type="fig" rid="F1">Figure 1F</xref>).</p>
</sec>
<sec id="s3-2">
<title>S1PR1-3 mediated signaling results in a decrease in parasite load</title>
<p>Our previous work demonstrated that S1P mediates anti-leishmanial activity in macrophages through reciprocal regulation of IL-10 and IL-12 (<xref ref-type="bibr" rid="B5">Arish et al., 2018</xref>). Additionally, we have further shown that S1PR2-3 signaling promotes M1 phenotype in THP-1 derived resting macrophages, which further reduces intracellular <italic>M. tuberculosis</italic> infection (<xref ref-type="bibr" rid="B2">Arish and Naz, 2022b</xref>). To further delineate the contribution of individual receptors, we employed selective agonists for S1PR1&#x2013;3. We found that all three receptors exerted anti-leishmanial effects to varying degrees (<xref ref-type="fig" rid="F2">Figures 2A&#x2013;E</xref>), with the S1PR2 agonist showing the most pronounced and statistically significant reduction in parasite load compared to control, S1PR1 or S1PR3-agonist treated THP-1&#x2013;derived infected macrophages (<xref ref-type="fig" rid="F2">Figures 2A&#x2013;E</xref>).</p>
<fig id="F2" position="float">
<label>FIGURE 2</label>
<caption>
<p>S1PR1-3 mediated signaling decreases parasite load: THP-1 derived macrophages were cultured on a cover-slip in six-well plates in the presence of <italic>L. donovani</italic> infection (MOI &#x3d; 1:10) for 6&#xa0;h, macrophages were washed to remove non-internalized parasites and incubated for next 24&#xa0;h in presence or absence of 10&#xa0;&#x3bc;M S1PR1, S1PR2, and S1PR3 agonist. <bold>(A)</bold> IM <bold>(B)</bold> S1PR1 agonist-treated infected macrophages <bold>(C)</bold> S1PR2 agonist-treated infected macrophages <bold>(D)</bold> S1PR3 agonist-treated infected macrophages <bold>(E)</bold> Graphical representation of percentage parasite load in infected and S1PR1-3-treated infected macrophages. Scale bar 10&#xa0;&#x3bc;m. The data is a representation of mean &#xb1; SD from three independent experiments &#x2a;, p&#x3c; 0.05; &#x2a;&#x2a;, p&#x3c; 0.01; ns non-significant.</p>
</caption>
<graphic xlink:href="fphar-17-1769137-g002.tif">
<alt-text content-type="machine-generated">Panel of four microscopic images labeled A, B, C, and D showing Giemsa stained infected macrophages. Adjacent bar graph labeled E displays parasitic load percentages for IM, S1PR1, S1PR2, and S1PR3 groups. IM shows the highest load, decreasing with S1PR1, S1PR2, and S1PR3. Asterisks indicate statistical significance.</alt-text>
</graphic>
</fig>
</sec>
</sec>
<sec sec-type="discussion" id="s4">
<title>Discussion</title>
<p>The hallmark of successful <italic>L. donovani</italic> infection is marked by suppression of protective pro-inflammatory immune responses together with enhanced anti-inflammatory signaling, which collectively favor parasite survival within host macrophages (<xref ref-type="bibr" rid="B9">da Silva et al., 2021</xref>). The later phenotypic changes are determined by key biomarkers of these responses, such as ERK-mediated IL-10 production that suppresses pro-inflammatory responses. <italic>Leishmania donovani</italic> strongly induces ERK1/2 phosphorylation in macrophages, which is further contributes to IL-10 production (<xref ref-type="bibr" rid="B31">Yang et al., 2007</xref>). In addition, IL-10 negatively regulates inflammatory cytokines such as IL-12 and TNF&#x3b1; (<xref ref-type="bibr" rid="B15">Kane and Mosser, 2001</xref>). Mice lacking the IL-10 gene have less parasitemia, and treatment of infected macrophages with recombinant IL-10 results in increased parasite load (<xref ref-type="bibr" rid="B15">Kane and Mosser, 2001</xref>). In our study, we found decreased phosphorylation in ERK1/2 and increased IL-10 levels in the <italic>L. donovani</italic>-infected macrophages, however, treatment of THP-1 derived macrophages with S1PR2-3 resulted in decreased ERK1/2 phosphorylation and decreased IL-10 production. However, S1PR1 agonist treatment does not alter ERK1/2 phosphorylation, also there was non-significant decrease in IL-10 levels in macrophages suggesting that S1PR1 is not regulating ERK1/2 pathway in <italic>L. donovani</italic> infected macrophages.</p>
<p>NF-kB family of transcription factors has been previously shown to regulate inflammatory responses such as TNF&#x3b1; and NO production (<xref ref-type="bibr" rid="B10">Dorrington and Fraser, 2019</xref>; <xref ref-type="bibr" rid="B30">Xie et al., 1994</xref>), which is critical for host-protection. P65 phosphorylation is necessary for NF-kB activation (<xref ref-type="bibr" rid="B33">Kwon et al., 2016</xref>), and it was showed that <italic>L. donovani</italic> reprograms the host epigenome, which in turn inhibits NF-kB activation and thus results in the absence of inflammatory response, which allows the parasite to thrive inside macrophages (<xref ref-type="bibr" rid="B18">Lecoeur et al., 2020</xref>). Activation of iNOS and proinflammatory cytokine production through NF-kB was observed in fucoidan, an immunomodulator obtained from <italic>Fucus vesiculosus</italic>, treated infected macrophages, which leads to suppression of intracellular parasite growth (<xref ref-type="bibr" rid="B26">Sharma et al., 2014</xref>). In this context, it could be speculated that activation of NF-kB by immunomodulators could regain the ability of macrophages to fight against infection. Similarly, we found a significant phosphorylation of the p65 subunit of NF-kB upon treatment of all the S1PR1-3 agonists, whereas low phosphorylation of p65 was detected in <italic>L. donovani</italic>-infected macrophages. Interestingly, S1PR1 and S1PR3 agonists do not induce much NO production as compared to S1PR2 agonist, which may be attributed to lower IL-10 levels in macrophages treated with these agonists, as IL-10 is known to suppress NO production (<xref ref-type="bibr" rid="B8">Cunha et al., 1992</xref>). Taken together, macrophages treated with an S1PR2 agonist show increased NO levels, potentially due to reduced IL-10 and elevated TNF&#x3b1; levels. However, further investigation is required to confirm these findings in primary macrophages.</p>
<p>Finally, treatment with S1PR1&#x2013;3 agonists led to a reduction in parasite load in infected macrophages, with the S1PR2 agonist producing the most pronounced clearance of intracellular parasites. This enhanced effect may be attributed to promote both NO secretion and TNF&#x3b1; production. While S1PR1 and S1PR3 activation also reduced parasite load, their effects are likely driven primarily by increased TNF&#x3b1; production. However, it is anticipated that some other mediators could be involved, as S1PR signaling can regulate macrophage polarization (<xref ref-type="bibr" rid="B2">Arish and Naz, 2022b</xref>). Although activation of all three S1PR isotypes reduced intracellular <italic>L. donovani</italic> burden, our data reveal clear receptor-specific differences in downstream inflammatory signaling. S1PR2 and S1PR3 activation markedly suppressed ERK1/2 phosphorylation and enhanced nitric oxide production, whereas S1PR1 exerted minimal effects on ERK1/2 signaling and NO generation. Despite this divergence, S1PR1 activation still significantly reduced parasite burden, indicating that parasite control can be achieved through distinct, non-redundant inflammatory pathways.</p>
<p>This differential behavior is consistent with established S1PR biology, wherein S1PR2 and S1PR3 preferentially engage signaling pathways that antagonize ERK-driven anti-inflammatory responses and promote NF-&#x3ba;B&#x2013;dependent antimicrobial functions, including nitric oxide production (<xref ref-type="bibr" rid="B32">Yang et al., 2018</xref>; <xref ref-type="bibr" rid="B2">Arish and Naz, 2022b</xref>). In contrast, S1PR1 primarily signals through G&#x3b1;i-dependent mechanisms and has been shown to modulate inflammatory responses independently of ERK1/2, potentially through TNF-&#x3b1;&#x2013;biased NF-&#x3ba;B activation (<xref ref-type="bibr" rid="B11">Gonzalez-Cabrera et al., 2008</xref>; <xref ref-type="bibr" rid="B27">Tian et al., 2023</xref>). The convergence on parasite reduction despite divergence in signaling underscores that restoration of macrophage antimicrobial capacity does not require uniform activation of all inflammatory pathways. Rather, selective engagement of receptor-specific S1PR signaling modules may be sufficient to limit intracellular parasite survival, highlighting the therapeutic relevance of receptor-targeted S1PR modulation.</p>
<p>S1P receptor signaling has previously been shown to influence macrophage polarization in Mtb infection including the promotion of inflammatory phenotypes via S1PR2 and S1PR3 (<xref ref-type="bibr" rid="B2">Arish and Naz, 2022b</xref>). In the present study, however, macrophage polarization was not directly assessed using canonical M1 or M2 markers. Instead, functional and signaling readouts relevant to leishmaniasis were evaluated, including ERK1/2 and NF-&#x3ba;B p65 activation, IL-10 and TNF-&#x3b1; production, and NO generation, which are well-established determinants of parasite survival in <italic>L. donovani&#x2013;</italic>infected macrophages.</p>
<p>Although macrophage polarization is critical for the elimination of infectious agents, an appropriately regulated inflammatory response is essential to prevent excessive tissue damage. While classically activated (M1) macrophages generate potent antimicrobial mediators such as nitric oxide and pro-inflammatory cytokines that aid in pathogen clearance, uncontrolled or prolonged activation can lead to collateral damage, chronic inflammation, and impaired tissue repair (<xref ref-type="bibr" rid="B17">Laskin et al., 2011</xref>). Conversely, alternatively activated (M2) macrophages contribute to the resolution of inflammation and tissue remodeling, but excessive skewing toward this phenotype may facilitate pathogen persistence and immune evasion. Therefore, a finely tuned balance between pro- and anti-inflammatory macrophage responses is fundamental to achieving effective host defense while preserving tissue integrity (<xref ref-type="bibr" rid="B17">Laskin et al., 2011</xref>). Taken together, our findings suggest that activation of S1PR1&#x2013;3 contributes to the reduction of intracellular parasite burden by promoting inflammatory responses in human macrophages, as evidenced by increased nitric oxide and TNF-&#x3b1; production. However, the present study has certain limitations. First, these observations require validation in primary human and murine macrophages to more comprehensively define the role of individual S1PR agonists. Furthermore, <italic>in vivo</italic> studies will be necessary to delineate the specific contributions of distinct S1PRs in regulating macrophage responses during <italic>L</italic>. <italic>donovani</italic> infection.</p>
</sec>
</body>
<back>
<sec sec-type="data-availability" id="s5">
<title>Data availability statement</title>
<p>The raw data supporting the conclusions of this article will be made available by the authors, without undue reservation.</p>
</sec>
<sec sec-type="ethics-statement" id="s6">
<title>Ethics statement</title>
<p>Ethical approval was not required for the studies on humans in accordance with the local legislation and institutional requirements because only commercially available established cell lines were used.</p>
</sec>
<sec sec-type="author-contributions" id="s7">
<title>Author contributions</title>
<p>MA: Writing &#x2013; original draft, Writing &#x2013; review and editing. FN: Writing &#x2013; review and editing, Writing &#x2013; original draft.</p>
</sec>
<ack>
<title>Acknowledgements</title>
<p>MA is thankful to the DHR Young Scientist Grant No. (Sanction No. R.12014/15/2018-HR).</p>
</ack>
<sec sec-type="COI-statement" id="s8">
<title>Conflict of interest</title>
<p>The author(s) declared that this work was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p>
</sec>
<sec sec-type="ai-statement" id="s9">
<title>Generative AI statement</title>
<p>The author(s) declared that generative AI was not used in the creation of this manuscript.</p>
<p>Any alternative text (alt text) provided alongside figures in this article has been generated by Frontiers with the support of artificial intelligence and reasonable efforts have been made to ensure accuracy, including review by the authors wherever possible. If you identify any issues, please contact us.</p>
</sec>
<sec sec-type="disclaimer" id="s10">
<title>Publisher&#x2019;s note</title>
<p>All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.</p>
</sec>
<fn-group>
<fn fn-type="custom" custom-type="edited-by">
<p>
<bold>Edited by:</bold> <ext-link ext-link-type="uri" xlink:href="https://loop.frontiersin.org/people/1788344/overview">Vunjia Tiong</ext-link>, Universiti Malaya, Malaysia</p>
</fn>
<fn fn-type="custom" custom-type="reviewed-by">
<p>
<bold>Reviewed by:</bold> <ext-link ext-link-type="uri" xlink:href="https://loop.frontiersin.org/people/3269836/overview">Jorge Rodriguez-Gonzalez</ext-link>, National Autonomous University of Mexico, Mexico</p>
<p>
<ext-link ext-link-type="uri" xlink:href="https://loop.frontiersin.org/people/3272747/overview">Soumya Kanti Ghosh</ext-link>, Wellcome Trust DBT India Alliance, India</p>
</fn>
</fn-group>
<ref-list>
<title>References</title>
<ref id="B1">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Arish</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Naz</surname>
<given-names>F.</given-names>
</name>
</person-group> (<year>2022a</year>). <article-title>Macrophage plasticity as a therapeutic target in tuberculosis</article-title>. <source>Eur. J. Immunol</source>. <pub-id pub-id-type="doi">10.1002/eji.202149624</pub-id>
<pub-id pub-id-type="pmid">35306661</pub-id>
</mixed-citation>
</ref>
<ref id="B2">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Arish</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Naz</surname>
<given-names>F.</given-names>
</name>
</person-group> (<year>2022b</year>). <article-title>Sphingosine-1-phosphate receptors 2 and 3 reprogram resting human macrophages into M1 phenotype following mycobacteria infection</article-title>. <source>Curr. Res. Immunol.</source> <volume>3</volume>, <fpage>110</fpage>&#x2013;<lpage>117</lpage>. <pub-id pub-id-type="doi">10.1016/j.crimmu.2022.05.004</pub-id>
<pub-id pub-id-type="pmid">35676924</pub-id>
</mixed-citation>
</ref>
<ref id="B3">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Arish</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Husein</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Kashif</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Saleem</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Akhter</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Rub</surname>
<given-names>A.</given-names>
</name>
</person-group> (<year>2016</year>). &#x201c;<article-title>Sphingosine-1-phosphate signaling: unraveling its role as a drug target against infectious diseases</article-title>,&#x201d;<source>Drug Discov. Today</source>, <volume>21</volume>, <fpage>133</fpage>&#x2013;<lpage>142</lpage>. <pub-id pub-id-type="doi">10.1016/j.drudis.2015.09.013</pub-id>
<pub-id pub-id-type="pmid">26456576</pub-id>
</mixed-citation>
</ref>
<ref id="B4">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Arish</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Alaidarous</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Ali</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Akhter</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Rub</surname>
<given-names>A.</given-names>
</name>
</person-group> (<year>2017</year>). <article-title>Implication of sphingosine-1-phosphate signaling in diseases: molecular mechanism and therapeutic strategies</article-title>. <source>J. Recept Signal Transduct. Res.</source> <volume>37</volume>, <fpage>437</fpage>&#x2013;<lpage>446</lpage>. <pub-id pub-id-type="doi">10.1080/10799893.2017.1358282</pub-id>
<pub-id pub-id-type="pmid">28758826</pub-id>
</mixed-citation>
</ref>
<ref id="B5">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Arish</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Husein</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Ali</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Tabrez</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Naz</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Ahmad</surname>
<given-names>M. Z.</given-names>
</name>
<etal/>
</person-group> (<year>2018</year>). <article-title>Sphingosine-1-phosphate signaling in Leishmania donovani infection in macrophages</article-title>. <source>PLoS Negl. Trop. Dis.</source> <volume>12</volume>, <fpage>e0006647</fpage>. <pub-id pub-id-type="doi">10.1371/journal.pntd.0006647</pub-id>
<pub-id pub-id-type="pmid">30118478</pub-id>
</mixed-citation>
</ref>
<ref id="B6">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bodhale</surname>
<given-names>N. P.</given-names>
</name>
<name>
<surname>Pal</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Kumar</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Chattopadhyay</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Saha</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Chattopadhyay</surname>
<given-names>N.</given-names>
</name>
<etal/>
</person-group> (<year>2018</year>). <article-title>Inbred mouse strains differentially susceptible to Leishmania donovani infection differ in their immune cell metabolism</article-title>. <source>Cytokine</source> <volume>112</volume>, <fpage>12</fpage>&#x2013;<lpage>15</lpage>. <pub-id pub-id-type="doi">10.1016/j.cyto.2018.06.003</pub-id>
<pub-id pub-id-type="pmid">29885992</pub-id>
</mixed-citation>
</ref>
<ref id="B7">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Carneiro</surname>
<given-names>M. B.</given-names>
</name>
<name>
<surname>Vaz</surname>
<given-names>L. G.</given-names>
</name>
<name>
<surname>Afonso</surname>
<given-names>L. C. C.</given-names>
</name>
<name>
<surname>Horta</surname>
<given-names>M. F.</given-names>
</name>
<name>
<surname>Vieira</surname>
<given-names>L. Q.</given-names>
</name>
</person-group> (<year>2021</year>). <article-title>Regulation of macrophage subsets and cytokine production in leishmaniasis</article-title>. <source>Cytokine</source> <volume>147</volume>, <fpage>155309</fpage>. <pub-id pub-id-type="doi">10.1016/j.cyto.2020.155309</pub-id>
<pub-id pub-id-type="pmid">33334669</pub-id>
</mixed-citation>
</ref>
<ref id="B8">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cunha</surname>
<given-names>F. Q.</given-names>
</name>
<name>
<surname>Moncada</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Liew</surname>
<given-names>F. Y.</given-names>
</name>
</person-group> (<year>1992</year>). <article-title>Interleukin-10 (IL-10) inhibits the induction of nitric oxide synthase by interferon-gamma in murine macrophages</article-title>. <source>Biochem. Biophys. Res. Commun.</source> <volume>182</volume> (<issue>182</issue>), <fpage>1155</fpage>&#x2013;<lpage>1159</lpage>. <pub-id pub-id-type="doi">10.1016/0006-291x(92)91852-h</pub-id>
<pub-id pub-id-type="pmid">1371674</pub-id>
</mixed-citation>
</ref>
<ref id="B9">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>da Silva</surname>
<given-names>R. L.</given-names>
</name>
<name>
<surname>Elizondo</surname>
<given-names>D. M.</given-names>
</name>
<name>
<surname>Brandy</surname>
<given-names>N. Z. D.</given-names>
</name>
<name>
<surname>Haddock</surname>
<given-names>N. L.</given-names>
</name>
<name>
<surname>Boddie</surname>
<given-names>T. A.</given-names>
</name>
<name>
<surname>de Oliveira</surname>
<given-names>L. L.</given-names>
</name>
<etal/>
</person-group> (<year>2021</year>). <article-title>Leishmania donovani infection suppresses allograft inflammatory Factor-1 in monocytes and macrophages to inhibit inflammatory responses</article-title>. <source>Sci. Rep.</source> <volume>11</volume> (<issue>11</issue>), <fpage>946</fpage>. <pub-id pub-id-type="doi">10.1038/s41598-020-79068-6</pub-id>
<pub-id pub-id-type="pmid">33441583</pub-id>
</mixed-citation>
</ref>
<ref id="B10">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Dorrington</surname>
<given-names>M. G.</given-names>
</name>
<name>
<surname>Fraser</surname>
<given-names>I. D. C.</given-names>
</name>
</person-group> (<year>2019</year>). <article-title>NF-&#x3ba;B signaling in macrophages: dynamics, crosstalk, and signal integration</article-title>. <source>Front. Immunol.</source> <volume>10</volume>, <fpage>705</fpage>. <pub-id pub-id-type="doi">10.3389/fimmu.2019.00705</pub-id>
<pub-id pub-id-type="pmid">31024544</pub-id>
</mixed-citation>
</ref>
<ref id="B11">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gonzalez-Cabrera</surname>
<given-names>P. J.</given-names>
</name>
<name>
<surname>Jo</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Sanna</surname>
<given-names>M. G.</given-names>
</name>
<name>
<surname>Brown</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Leaf</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Marsolais</surname>
<given-names>D.</given-names>
</name>
<etal/>
</person-group> (<year>2008</year>). <article-title>Full pharmacological efficacy of a novel S1P1 agonist that does not require S1P-like headgroup interactions</article-title>. <source>Mol. Pharmacol.</source> <volume>74</volume>, <fpage>1308</fpage>&#x2013;<lpage>1318</lpage>. <pub-id pub-id-type="doi">10.1124/mol.108.049783</pub-id>
<pub-id pub-id-type="pmid">18708635</pub-id>
</mixed-citation>
</ref>
<ref id="B12">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gupta</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Srivastav</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Saha</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Das</surname>
<given-names>P. K.</given-names>
</name>
<name>
<surname>Ukil</surname>
<given-names>A.</given-names>
</name>
</person-group> (<year>2016</year>). <article-title>Leishmania donovani inhibits macrophage apoptosis and pro-inflammatory response through AKT-Mediated regulation of &#x3b2;-catenin and FOXO-1</article-title>. <source>Cell Death Differ.</source> <volume>23</volume>, <fpage>1815</fpage>&#x2013;<lpage>1826</lpage>. <pub-id pub-id-type="doi">10.1038/cdd.2016.101</pub-id>
<pub-id pub-id-type="pmid">27662364</pub-id>
</mixed-citation>
</ref>
<ref id="B13">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Jo</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Bhhatarai</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Repetto</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Guerrero</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Riley</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Brown</surname>
<given-names>S. J.</given-names>
</name>
<etal/>
</person-group> (<year>2012</year>). <article-title>Novel selective allosteric and bitopic ligands for the S1P(3) receptor</article-title>. <source>ACS Chem. Biol.</source> <volume>21</volume> (<issue>7</issue>), <fpage>1975</fpage>&#x2013;<lpage>1983</lpage>. <pub-id pub-id-type="doi">10.1021/cb300392z</pub-id>
<pub-id pub-id-type="pmid">22971058</pub-id>
</mixed-citation>
</ref>
<ref id="B14">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Jones</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Adcock</surname>
<given-names>I. M.</given-names>
</name>
<name>
<surname>Ahmed</surname>
<given-names>B. Y.</given-names>
</name>
<name>
<surname>Punchard</surname>
<given-names>N. A.</given-names>
</name>
</person-group> (<year>2007</year>). <article-title>Modulation of LPS stimulated NF-kappaB mediated nitric oxide production by PKCepsilon and JAK2 in RAW macrophages</article-title>. <source>J. Inflamm. (Lond)</source> <volume>4</volume>, <fpage>23</fpage>. <pub-id pub-id-type="doi">10.1186/1476-9255-4-23</pub-id>
<pub-id pub-id-type="pmid">18036230</pub-id>
</mixed-citation>
</ref>
<ref id="B15">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kane</surname>
<given-names>M. M.</given-names>
</name>
<name>
<surname>Mosser</surname>
<given-names>D. M.</given-names>
</name>
</person-group> (<year>2001</year>). <article-title>The role of IL-10 in promoting disease progression in leishmaniasis</article-title>. <source>J. Immunol.</source> <volume>15</volume> (<issue>166</issue>), <fpage>1141</fpage>&#x2013;<lpage>1147</lpage>. <pub-id pub-id-type="doi">10.4049/jimmunol.166.2.1141</pub-id>
<pub-id pub-id-type="pmid">11145695</pub-id>
</mixed-citation>
</ref>
<ref id="B33">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kwon</surname>
<given-names>H. J.</given-names>
</name>
<name>
<surname>Choi</surname>
<given-names>G. E.</given-names>
</name>
<name>
<surname>Ryu</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Kwon</surname>
<given-names>S. J.</given-names>
</name>
<name>
<surname>Kim</surname>
<given-names>S. C.</given-names>
</name>
<name>
<surname>Booth</surname>
<given-names>C.</given-names>
</name>
<etal/>
</person-group> (<year>2016</year>). <article-title>Stepwise phosphorylation of p65 promotes NF-kappaB activation and NK cell responses during target cell recognition</article-title>. <source>Nat Commun.</source> <volume>7</volume>, <fpage>11686</fpage>. <pub-id pub-id-type="doi">10.1038/ncomms11686</pub-id>
<pub-id pub-id-type="pmid">27221592</pub-id>
</mixed-citation>
</ref>
<ref id="B16">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lang</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Hellio</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Kaye</surname>
<given-names>P. M.</given-names>
</name>
<name>
<surname>Antoine</surname>
<given-names>J. C.</given-names>
</name>
</person-group> (<year>1994</year>). <article-title>Leishmania donovani-infected macrophages: characterization of the parasitophorous vacuole and potential role of this organelle in antigen presentation</article-title>. <source>J. Cell Sci.</source> <volume>107</volume> (<issue>Pt 8</issue>), <fpage>2137</fpage>&#x2013;<lpage>2150</lpage>. <pub-id pub-id-type="doi">10.1242/jcs.107.8.2137</pub-id>
<pub-id pub-id-type="pmid">7983173</pub-id>
</mixed-citation>
</ref>
<ref id="B17">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Laskin</surname>
<given-names>D. L.</given-names>
</name>
<name>
<surname>Sunil</surname>
<given-names>V. R.</given-names>
</name>
<name>
<surname>Gardner</surname>
<given-names>C. R.</given-names>
</name>
<name>
<surname>Laskin</surname>
<given-names>J. D.</given-names>
</name>
</person-group> (<year>2011</year>). <article-title>Macrophages and tissue injury: agents of defense or destruction?</article-title> <source>Annu. Rev. Pharmacol. Toxicol.</source> <volume>51</volume>, <fpage>267</fpage>&#x2013;<lpage>288</lpage>. <pub-id pub-id-type="doi">10.1146/annurev.pharmtox.010909.105812</pub-id>
<pub-id pub-id-type="pmid">20887196</pub-id>
</mixed-citation>
</ref>
<ref id="B18">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lecoeur</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Prina</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Rosazza</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Kokou</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>N&#x27;Diaye</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Aulner</surname>
<given-names>N.</given-names>
</name>
<etal/>
</person-group> (<year>2020</year>). <article-title>Targeting macrophage histone H3 modification as a leishmania strategy to dampen the NF-&#x3ba;B/NLRP3-Mediated inflammatory response</article-title>. <source>Cell Rep.</source> <volume>30</volume>, <fpage>1870</fpage>&#x2013;<lpage>1882.e1874</lpage>. <pub-id pub-id-type="doi">10.1016/j.celrep.2020.01.030</pub-id>
<pub-id pub-id-type="pmid">32049017</pub-id>
</mixed-citation>
</ref>
<ref id="B19">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Li</surname>
<given-names>Y. H.</given-names>
</name>
<name>
<surname>Yan</surname>
<given-names>Z. Q.</given-names>
</name>
<name>
<surname>Brauner</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Tullus</surname>
<given-names>K.</given-names>
</name>
</person-group> (<year>2002</year>). <article-title>Activation of macrophage nuclear factor-kappa B and induction of inducible nitric oxide synthase by LPS</article-title>. <source>Respir. Res.</source> <volume>3</volume>, <fpage>23</fpage>. <pub-id pub-id-type="doi">10.1186/rr173</pub-id>
<pub-id pub-id-type="pmid">12323081</pub-id>
</mixed-citation>
</ref>
<ref id="B20">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lin</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Peng</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Zhu</surname>
<given-names>Q.</given-names>
</name>
<name>
<surname>Pan</surname>
<given-names>X.</given-names>
</name>
</person-group> (<year>2024</year>). <article-title>S1PR2 participates in intestinal injury in severe acute pancreatitis by regulating macrophage pyroptosis</article-title>. <source>Front. Immunol.</source> <volume>15</volume>, <fpage>1405622</fpage>. <pub-id pub-id-type="doi">10.3389/fimmu.2024.1405622</pub-id>
<pub-id pub-id-type="pmid">38827741</pub-id>
</mixed-citation>
</ref>
<ref id="B21">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>McGinley</surname>
<given-names>M. P.</given-names>
</name>
<name>
<surname>Cohen</surname>
<given-names>J. A.</given-names>
</name>
</person-group> (<year>2021</year>). <article-title>Sphingosine 1-phosphate receptor modulators in multiple sclerosis and other conditions</article-title>. <source>Lancet</source> <volume>398</volume> (<issue>398</issue>), <fpage>1184</fpage>&#x2013;<lpage>1194</lpage>. <pub-id pub-id-type="doi">10.1016/S0140-6736(21)00244-0</pub-id>
<pub-id pub-id-type="pmid">34175020</pub-id>
</mixed-citation>
</ref>
<ref id="B22">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Naz</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Arish</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Hassan</surname>
<given-names>I.</given-names>
</name>
</person-group> (<year>2024</year>). <article-title>Editorial: sphingolipids in infections, diseases, and disorders</article-title>. <source>Front. Immunol.</source> <volume>15</volume>, <fpage>1392055</fpage>. <pub-id pub-id-type="doi">10.3389/fimmu.2024.1392055</pub-id>
<pub-id pub-id-type="pmid">38550595</pub-id>
</mixed-citation>
</ref>
<ref id="B23">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Palomino-Cano</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Moreno</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Irache</surname>
<given-names>J. M.</given-names>
</name>
<name>
<surname>Espuelas</surname>
<given-names>S.</given-names>
</name>
</person-group> (<year>2024</year>). <article-title>Targeting and activation of macrophages in leishmaniasis. A focus on iron oxide nanoparticles</article-title>. <source>Front. Immunol.</source> <volume>15</volume>, <fpage>1437430</fpage>. <pub-id pub-id-type="doi">10.3389/fimmu.2024.1437430</pub-id>
<pub-id pub-id-type="pmid">39211053</pub-id>
</mixed-citation>
</ref>
<ref id="B24">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Reinhard</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Huber</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Lohoff</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Visekruna</surname>
<given-names>A.</given-names>
</name>
</person-group> (<year>2012</year>). <article-title>The role of NF-&#x3ba;B activation during protection against leishmania infection</article-title>. <source>Int. J. Med. Microbiol.</source> <volume>302</volume>, <fpage>230</fpage>&#x2013;<lpage>235</lpage>. <pub-id pub-id-type="doi">10.1016/j.ijmm.2012.07.006</pub-id>
<pub-id pub-id-type="pmid">22901377</pub-id>
</mixed-citation>
</ref>
<ref id="B25">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Satsu</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Schaeffer</surname>
<given-names>M. T.</given-names>
</name>
<name>
<surname>Guerrero</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Saldana</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Eberhart</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Hodder</surname>
<given-names>P.</given-names>
</name>
<etal/>
</person-group> (<year>2013</year>). <article-title>A sphingosine 1-phosphate receptor 2 selective allosteric agonist</article-title>. <source>Bioorg Med. Chem.</source> <volume>21</volume>, <fpage>5373</fpage>&#x2013;<lpage>5382</lpage>. <pub-id pub-id-type="doi">10.1016/j.bmc.2013.06.012</pub-id>
<pub-id pub-id-type="pmid">23849205</pub-id>
</mixed-citation>
</ref>
<ref id="B26">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sharma</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Kar</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Basu</surname>
<given-names>B. W.</given-names>
</name>
<name>
<surname>Ghosh</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Das</surname>
<given-names>P. K.</given-names>
</name>
</person-group> (<year>2014</year>). <article-title>The curative effect of fucoidan on visceral leishmaniasis is mediated by activation of MAP kinases through specific protein kinase C isoforms</article-title>. <source>Cell Mol. Immunol.</source> <volume>11</volume>, <fpage>263</fpage>&#x2013;<lpage>274</lpage>. <pub-id pub-id-type="doi">10.1038/cmi.2013.68</pub-id>
<pub-id pub-id-type="pmid">24561457</pub-id>
</mixed-citation>
</ref>
<ref id="B27">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tian</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Chang</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Xu</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Huang</surname>
<given-names>T.</given-names>
</name>
<etal/>
</person-group> (<year>2023</year>). <article-title>S1P/S1PR1 axis promotes macrophage M1 polarization through NLRP3 inflammasome activation in lupus nephritis</article-title>. <source>Mol. Immunol.</source> <volume>160</volume>, <fpage>55</fpage>&#x2013;<lpage>66</lpage>. <pub-id pub-id-type="doi">10.1016/j.molimm.2023.06.006</pub-id>
<pub-id pub-id-type="pmid">37379683</pub-id>
</mixed-citation>
</ref>
<ref id="B28">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wang</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>He</surname>
<given-names>Q.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Yu</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Cang</surname>
<given-names>J.</given-names>
</name>
<etal/>
</person-group> (<year>2023</year>). <article-title>Inhibition of sphingosine-1-phosphate receptor 3 suppresses ATP-induced NLRP3 inflammasome activation in macrophages</article-title>. <source>Front. Immunol.</source> <volume>14</volume>, <fpage>1090202</fpage>. <pub-id pub-id-type="doi">10.3389/fimmu.2023.1090202</pub-id>
<pub-id pub-id-type="pmid">36798132</pub-id>
</mixed-citation>
</ref>
<ref id="B29">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Weigert</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Olesch</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Br&#xfc;ne</surname>
<given-names>B.</given-names>
</name>
</person-group> (<year>2019</year>). <article-title>Sphingosine-1-Phosphate and macrophage biology-how the sphinx tames the big eater</article-title>. <source>Front. Immunol.</source> <volume>10</volume>, <fpage>1706</fpage>. <pub-id pub-id-type="doi">10.3389/fimmu.2019.01706</pub-id>
<pub-id pub-id-type="pmid">31379883</pub-id>
</mixed-citation>
</ref>
<ref id="B30">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Xie</surname>
<given-names>Q. W.</given-names>
</name>
<name>
<surname>Kashiwabara</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Nathan</surname>
<given-names>C.</given-names>
</name>
</person-group> (<year>1994</year>). <article-title>Role of transcription factor NF-kappa B/Rel in induction of nitric oxide synthase</article-title>. <source>J. Biol. Chem. Feb</source> <volume>18</volume>, <fpage>4705</fpage>&#x2013;<lpage>4708</lpage>. <pub-id pub-id-type="doi">10.1016/S0021-9258(17)37600-7</pub-id>
<pub-id pub-id-type="pmid">7508926</pub-id>
</mixed-citation>
</ref>
<ref id="B31">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yang</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Mosser</surname>
<given-names>D. M.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>X.</given-names>
</name>
</person-group> (<year>2007</year>). <article-title>Activation of the MAPK, ERK, following Leishmania amazonensis infection of macrophages</article-title>. <source>J. Immunol. Jan.</source> <volume>15</volume> (<issue>178</issue>), <fpage>1077</fpage>&#x2013;<lpage>1085</lpage>. <pub-id pub-id-type="doi">10.4049/jimmunol.178.2.1077</pub-id>
<pub-id pub-id-type="pmid">17202371</pub-id>
</mixed-citation>
</ref>
<ref id="B32">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yang</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Tian</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Ji</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>L.</given-names>
</name>
</person-group> (<year>2018</year>). <article-title>Sphingosine 1-Phosphate (S1P)/S1P Receptor2/3 axis promotes inflammatory M1 polarization of bone marrow-derived Monocyte/Macrophage <italic>via</italic> G(&#x3b1;)i/o/PI3K/JNK pathway</article-title>. <source>Cell Physiol. Biochem.</source> <volume>49</volume>, <fpage>1677</fpage>&#x2013;<lpage>1693</lpage>. <pub-id pub-id-type="doi">10.1159/000493611</pub-id>
<pub-id pub-id-type="pmid">30231248</pub-id>
</mixed-citation>
</ref>
</ref-list>
</back>
</article>